Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?

Why Bristol-Myers Squibb Stock Is Stumbling Ahead of Earnings

APA Corporation

Carnival

Halliburton

Kroger

Simon Property Group

According to GuruFocus’ list of 52-week lows, these guru stocks have reached their 52-week lows.

52-Week Company Lows (July 21)

Investors will focus on regular top- and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports second-quarter results.

Is a Beat in the Cards for Bristol-Myers (BMY) Q2 Earnings?

Bayer AG

Bristol-Myers (BMY), Ono Pharmaceutical and Bayer ink a collaboration deal to evaluate the combination of Opdivo plus Stivarga for treating micro-satellite stable metastatic colorectal cancer.

Bristol-Myers, Ono, Bayer Team Up for Colorectal Cancer Study

Bank of New York Mellon

State Street

According to GuruFocus' list of 52-week lows, these Guru stocks have reached their 52-week lows.

52-Week Company Lows (July 14)

Oshkosh

QUALCOMM

A drugmaker, a chipmaker, and a truck manufacturer are worth watching this month.

3 U.S. Stocks to Watch in July

Eli Lilly

Merck

Pfizer

Investors' skepticism runs rife as Trump drops the drug rebate proposal, pushing drugmakers to take center stage with regard to the controversial drug pricing issue.

Drug Pricing Woes Linger on Repealing Drug Rebate Proposal

Bristol-Myers (BMY) declines on uncertainty and delay of the Celgene merger.

Bristol-Myers (BMY) Down 11.6% YTD: What Lies Ahead in 2H19?

Drug stocks are falling on fears of President Trump's next move on drug prices. Here's a look at the charts.

4 Drug Stocks Getting Smashed

AbbVie

Teva Pharmaceutical

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials.

Big Pharma Sees Rising Tide in Short Interest

Allergan

Amgen

Biogen

Celgene

Gilead Sciences

With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

Will Patent Woes Boost Pharma Stock Megamergers Further?

Spark Therapeutics

Roche Holding AG

Vertex Pharmaceuticals

Biotech companies exploded with "megadeals" in the first half of 2019 as pharmaceutical companies Bristol-Myers Squibb and AbbVie announced acquisitions worth a combined $137 billion.
The post Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019 appeared first on Investor's Business Daily.

Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019

In the latest trading session, Bristol-Myers Squibb (BMY) closed at $45.77, marking a -0.26% move from the previous day.

Bristol-Myers Squibb (BMY) Stock Moves -0.26%: What You Should Know

Wall Street clearly isn't pleased with Bristol's acquisition of Celgene.

Why Bristol-Myers Squibb Stock Plunged in the First Half of 2019

Black Stone Minerals LP

Chemours

Sprouts Farmers Markets

Details the lows for the following companies: Bristol-Myers Squibb, Simon Property Group, Kroger, The Chemours Co., Black Stone Minerals and Sprouts Farmers Market.

52-Week Company Lows (July 7)

Johnson & Johnson

Rogers

Novo Nordisk

Novartis

Sanofi

Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.

The Top 10 Biotechnology Companies (JNJ, ROG.VX)

Bristol-Myers Squibb is acquiring Celgene in a deal that will create a true pharmaceutical powerhouse.

Bristol-Myers Squibb Is Cheap

After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.

Will the Pharma Space Witness More Mega-Merger Deals in 2H?

Iron Mountain

According to GuruFocus’ list of 52-week lows, these Guru stocks have reached their 52-week lows.

52-Week Company Lows (June 30)

Some of the drugs aren't going to survive this marriage.

The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)

Bristol-Myers Squibb’s  (NYSE:BMY) oncology drugs business is its largest therapeutic area, and it will likely grow in mid-single-digits from about $10.3 billion in 2018 to $12.4 billion in 2021, according to Trefis estimates. This growth will likely be driven by higher sales of Opdivo.

How Does Bristol-Myers Squibb's Oncology Drugs Portfolio Compare To Its Peers?

Bristol-Myers (BMY) declines as it announces to sell Otezla to settle FTC concerns, while Opdivo fails in liver cancer study.

Bristol-Myers to Sell Otezla for Celgene Merger, Shares Down

Bad news comes in threes for Bristol-Myers and Celgene.

Bristol-Myers Squibb had some bad news for investors

Caesars Entertainment

Match Group

New Relic

Bristol-Myers Squibb, Celgene, Caesars Entertainment, Match Group and New Relic are our top stock trades for Tuesday.

5 Top Stock Trades for Tuesday

The $74 billion merger of Bristol-Myers Squibb and Celgene has been delayed as FTC pushback spurred Celgene to divest a major psoriasis drug.

News for Bristol-Myers Stock (BMY)